Year-end Sale % OFF 
Abstract
The incidence and methods available for the diagnosis of metastatic prostate cancer, together with the development and efficacy of various treatments, are discussed. In patients with good prognostic characteristics, maximal androgen deprivation, with blockade of both testicular and adrenal androgens, seems to be the favored approach. Surgical castration, although effective, seems inferior to depot luteinizing hormone-releasing hormone therapy with respect to patients’ acceptance and preference. Nonsteroidal antiandrogens, such as flutamide, have advantages over steroidal compounds both in efficacy and side effects. Recent studies have demonstrated that combination therapy may be superior in terms of progression-free survival and overall survival in patients with metastatic prostate cancer.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
